tecnet equity

What they fund

Early-stage B2B tech companies with a working prototype or proof-of-concept, receiving initial equity investments of approx. €300,000 [1]., Life sciences start-ups and spin-offs, including areas like Cell & Gene Therapy, Medical Devices, and Pharmaceuticals [1]., Very young start-ups in Lower Austria seeking rapid financing via a €50,000 SAFE before their first seed round [1]., Growth-oriented startups requiring follow-on funding, with a total investment capacity of up to €3 million [1].

Investment thesis

tecnet Venture Capital is an industry-independent early-stage venture capital fund that partners with innovative companies to shape the future and create sustainable value, leveraging its role as a domestic catalyst with an international network [1].

• Sector Focus — The fund primarily invests in innovative B2B technologies, life sciences start-ups and spin-offs, covering sectors like AI, SaaS, Cloud, Data Analytics, IoT, Climate Tech, and various BioTech fields [1].
• Stage & Ticket Size — They provide initial investments of approximately €300,000, with a total investment capacity of up to €3 million, and offer a €50,000 SAFE for very young start-ups [1].
• Active Partnership — tecnet acts as a lead or co-investor, actively participating in follow-on rounds and providing support beyond equity capital through its extensive experience and network [1].
• Exit Horizon — The typical investment period is up to eight years, with exits pursued via trade sales, secondary sales, or IPOs [1].

Credibility: The investment thesis, focus areas, ticket sizes, and exit strategy are explicitly detailed on the tecnet Venture Capital webpage [1].

Value add

tecnet provides a comprehensive suite of support beyond equity capital, leveraging its extensive experience, collaborations with research institutions, and an expansive international network [1].

Fit verdict: Ideal for Austrian B2B tech and life sciences founders seeking patient capital and strategic guidance through an 8-year horizon.

Founder diligence script:

• How does tecnet's network specifically accelerate market entry for B2B tech in the DACH region?
• What is the typical timeline from term sheet to funding for a €300,000 investment?
• How does tecnet structure follow-on rounds to support growth up to the €3 million cap?
• What specific research institution collaborations can be leveraged for our life sciences spin-off?

Portfolio focus

Nexufend, Propcorn, Sipfront, Circly, ESG Plus, Farmdok, Greenwood Power, Orderlion, Ribbon Biolabs, Sarcura, Shopstory, Corplife, Valanx, Sheepblue, Foex, indoo.rs, Jeder, nxt Control, Sipwise, Wikitude [1]

Notable investments & exits

Nexufend, Propcorn, Sipfront, Circly, ESG Plus, Farmdok, Greenwood Power, Orderlion, Ribbon Biolabs, Sarcura, Shopstory, Corplife, Valanx, Sheepblue, Foex, indoo.rs, Jeder, nxt Control, Sipwise, Wikitude [1]

Strategic implications

tecnet's focus on B2B tech and life sciences positions it as a key player in Austria's deep tech ecosystem, particularly for spin-offs from research institutions. The €50k SAFE product is a strategic move to capture very early-stage deals, potentially creating a pipeline for larger follow-on investments. The 8-year horizon suggests a patient capital approach, which is advantageous for deep tech and life sciences but may limit flexibility for faster-moving sectors. The lack of disclosed fund size and LP information indicates a private, possibly state-backed or corporate-funded structure, which may influence investment criteria and risk appetite.

Where they could go further

tecnet could enhance its value proposition by formalizing its research institution collaborations into a structured innovation partnership program. The firm should consider expanding its geographic focus beyond Lower Austria to capture more national and international opportunities, given its stated international network. tecnet could improve transparency by disclosing more details about its exit track record, including specific outcomes and timelines for notable exits. The firm might benefit from developing a more structured co-investment strategy to leverage its network and reduce risk in larger deals.